Below, in their own words, is how we assisted rare blood disorder gene therapy uniQure Biopharma, launch and accelerate 4-6 months off of their study start-up. For more examples of our clients, see our collaborators page

When I started, we were planning to move into Phase 3, so we definitely needed a foothold in the USA. When I started, we knew nothing about genetic therapy. And the team (again, all in Europe at the time) knew nothing about USA regulations. We were basically stuck. I did my research and found a few people who offered support for IBC services.

We initially went towards a large firm as a way to centralize services, but we quickly realized that the firm wasn’t as centralized as we had thought, and more importantly, the firm did not support sites who had their own IBC.

CBS was different. Chris spent time with me, he came out and educated my newly formed USA team (and my Amsterdam based team by phone) around the IBC regulations. He helped us write an IBC executive summary, which has sped us through every IBC we have submitted to (1st pass approval every time so far). He also helped us write the Appendix M.

All things we didn’t really know how to do.

But what really set CBS apart has been their “white glove” service for sites. Many of our sites have their own IBCs, but not all of those IBCs are as organized as we would like – coupled with the fact that many of our coordinators have not worked on gene therapy before, so didn’t know how to fill out the form. CBS has supported each of those sites as much as they required. In some cases, that was fully completing the form. In other cases, it mean just proofreading it, and in some cases, it was just inserting a couple of lines in some sections.

It was this boutique style that sets them apart. It has had a direct effect in making our study successfully navigate difficult timelines, and it has done wonders for building our reputation as a sponsor who wants to help.

Honestly, don’t look back. Grab up CBS. You won’t regret it.

Raul P. Lima, MA, MBA
VP, Global Head of Clinical Operations

Contact Us For More Stories Like This

Mission Statement

Our mission and expertise at Clinical Biosafety Services is to provide accelerated, compliant review of gene transfer/gene therapy clinical trials to a convened review of a site-specific Institutional Biosafety Committee (IBC). We do this by understanding the challenges in the two client relationship of serving an institution and a sponsor.

Our focus is to accelerate the trial, and remove regulatory burden and uncertainty by having our highly trained experts provide friendly, knowledgeable support during the review process. We understand these therapeutics will change medicine, and our service is to bring the trial to enrollment fruition, quickly and compliantly.